PLATINUM Trial

Uses

Preparation

Comparisons

Background

Highlighted claims

• PLATINUM was a prospective, randomised, double-blind, placebo-controlled, parallel-group trial conducted at 16 emergency department sites across the United States. — Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department
• The trial was terminated early because COVID-19 pandemic conditions made enrolment difficult, leaving it underpowered. — Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department
• The modified intention-to-treat population contained 111 patients: 53 in the patiromer group and 58 in the placebo group. — Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department
• Eligible participants were adults aged 18 or older with serum potassium of at least 5.8 mEq/L presenting to a participating emergency department. — Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department
• All participants received standard combination therapy (dextrose, insulin, and albuterol) before receiving either patiromer or placebo. — Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department
• Sixty participants per arm were calculated to provide 90% power, but the study planned to enrol 150 per arm to compensate for expected 60% attrition. — Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department